Are Progression/Regression Studies “Good Enough” Surrogates for Rcts With Clinical Endpoints?
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker's Bureau - Amgen; AstraZenca; Pfizer; Bayer AG